Seagen  logo
Seagen SGEN

Quarterly report 2023-Q3
added 05-16-2026

report update icon

Seagen Income Statement 2011-2026 | SGEN

Annual Income Statement Seagen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

26.3 B 23.5 B 26.4 B 18.8 B 11.7 B 7.73 B 9.24 B 3.9 B 4.47 B 6.39 B 3.32 B 2.09 B - - -

Shares

185 M 182 M 175 M 165 M 158 M 143 M 141 M 129 M 123 M 122 M 118 M 113 M 101 M - -

Historical Prices

142 129 151 114 74.3 54 65.7 30.2 36.2 52.6 28.1 18.5

Net Income

-610 M -674 M 614 M -159 M -223 M -126 M -140 M -120 M -76.1 M -62.5 M -53.8 M -152 M -66.3 M -81.7 M -

Revenue

1.96 B 1.57 B 2.18 B 917 M 655 M 130 M 105 M 337 M 287 M 269 M 211 M 94.8 M 107 M 52 M -

Cost of Revenue

410 M 312 M 218 M 44 M 88.3 M - - - - - - - - - -

Gross Profit

- - - 873 M 566 M 428 M 376 M 299 M 258 M 248 M 197 M 91.7 M - - -

Operating Income

-613 M -682 M 597 M -221 M -260 M -196 M -143 M -121 M -77.4 M -62.9 M -57.3 M -144 M -68.2 M -84.9 M -

EBITDA

-566 M -639 M 633 M -197 M -234 M -172 M -125 M -106 M -64.9 M -54.2 M -51.1 M -140 M -64.6 M -81.6 M -

Operating Expenses

- - - 1.09 B 826 M 624 M 519 M 420 M 335 M 311 M 255 M 236 M - - -

General and Administrative Expenses

821 M 716 M 534 M 374 M 261 M 167 M 139 M 126 M 104 M 92.4 M 84.3 M 72.7 M 29.3 M 17.7 M -

All numbers in USD currency

Quarterly Income Statement Seagen

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

188 M 188 M 187 M 187 M 185 M 184 M 184 M 183 M 182 M 182 M 181 M 181 M 174 M 173 M 172 M 172 M 168 M 161 M 161 M 160 M 159 M 158 M 152 M 144 M 143 M 143 M 142 M 142 M 141 M 140 M 140 M 140 M 128 M 125 M 124 M 124 M 124 M 123 M 123 M 123 M 122 M 121 M 120 M 120 M 118 M 117 M 117 M 116 M 115 M 114 M 109 M

Net Income

-216 M -212 M -175 M - -191 M -135 M -136 M - -294 M -84.6 M -121 M 167 M 636 M -21.2 M -168 M 25.8 M -91.9 M -79.2 M -13.3 M -120 M -67.4 M 76.3 M -112 M -59.2 M 50 M -56.4 M -60 M -55.1 M -31.8 M -32.7 M -20.5 M -24.9 M -26.4 M -47.5 M -21.7 M -26.7 M -15.6 M -17.6 M -16.3 M -15.7 M -23.7 M -6.9 M -16.3 M -10.6 M -13.7 M -17.2 M -12.3 M -27.2 M -40.7 M -51.5 M -32.7 M

Revenue

649 M 604 M 520 M - 510 M 498 M 426 M - 424 M 388 M 332 M 601 M 1.06 B 278 M 235 M 290 M 213 M 218 M 195 M 175 M 169 M 170 M 141 M 130 M 135 M 108 M 109 M 105 M 106 M 95.4 M 111 M 93.5 M 84.1 M 77.1 M 82.2 M 74.3 M 75.9 M 68.3 M 68.3 M 67.4 M 71 M 73.6 M 57.3 M 63.9 M 49.8 M 48.8 M 48.2 M 48.9 M 20.7 M 13.1 M 12.2 M

Cost of Revenue

165 M 181 M 112 M - 108 M 106 M 87.6 M - 82.6 M 78.1 M 64.1 M - 78.3 M 48.2 M 29.4 M - 10.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-231 M -221 M -185 M - -193 M -133 M -133 M - -298 M -89.6 M -122 M - 638 M -94 M -112 M - -89.8 M -38.7 M -53.6 M - -45.6 M -30.3 M -93.8 M - -32.2 M -59.3 M -59.3 M - -32.4 M -33.4 M -21 M - -26.5 M -47.6 M -21.7 M - -15.6 M -17.6 M -16.4 M - -23.8 M -7.01 M -16.4 M - -13.8 M -17.3 M -15.5 M - -40.9 M -51.8 M -33 M

EBITDA

-193 M -196 M -172 M - -158 M -110 M -122 M - -268 M -70 M -113 M - 664 M -77.4 M -106 M - -75.6 M -28.8 M -48.7 M - -26.5 M -16.5 M -86.8 M - -15.8 M -49.1 M -54.5 M - -19.1 M -24.8 M -16.8 M - -15.7 M -40.5 M -18.3 M - -6.52 M -11.7 M -13.5 M - -17.7 M -3.17 M -14.7 M - -9.2 M -14.3 M -14 M - -38.2 M -50 M -32.1 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 64.8 M 45.1 M

General and Administrative Expenses

266 M 244 M 236 M - 210 M 220 M 174 M - 180 M 165 M 160 M - 128 M 126 M 122 M - 96.1 M 82.3 M 80.3 M - 57.2 M 58.3 M 66.2 M - 39.7 M 40.7 M 38.4 M - 34.8 M 33.3 M 29.7 M - 29.7 M 30.3 M 32.1 M - 25.3 M 25.5 M 24 M - 21.5 M 23.5 M 21.9 M - 18.8 M 19.9 M 22.2 M - 19.8 M 15.2 M 12.7 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Seagen (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.57 -3.68 % $ 184 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 16.87 -2.49 % $ 789 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.47 -4.6 % $ 205 M israelIsrael
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 30.26 1.0 % $ 814 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Exelixis Exelixis
EXEL
$ 50.13 -1.9 % $ 13.6 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.41 4.78 % $ 67.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Forte Biosciences Forte Biosciences
FBRX
$ 23.11 -3.55 % $ 299 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 4.09 -7.05 % $ 1.22 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.63 2.52 % $ 434 M britainBritain
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioNTech SE BioNTech SE
BNTX
$ 89.55 -2.65 % $ 21.6 B germanyGermany
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.17 -7.66 % $ 139 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Gilead Sciences Gilead Sciences
GILD
$ 129.58 -1.88 % $ 161 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.36 -3.72 % $ 5.53 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.72 -1.58 % $ 32.9 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.12 - $ 649 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Genmab A/S Genmab A/S
GMAB
$ 26.54 -1.34 % $ 1.72 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA